Carolyn A. Buser

5.1k total citations
47 papers, 2.6k citations indexed

About

Carolyn A. Buser is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Carolyn A. Buser has authored 47 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 16 papers in Oncology and 16 papers in Cell Biology. Recurrent topics in Carolyn A. Buser's work include Microtubule and mitosis dynamics (11 papers), Cancer-related Molecular Pathways (10 papers) and Protein Kinase Regulation and GTPase Signaling (8 papers). Carolyn A. Buser is often cited by papers focused on Microtubule and mitosis dynamics (11 papers), Cancer-related Molecular Pathways (10 papers) and Protein Kinase Regulation and GTPase Signaling (8 papers). Carolyn A. Buser collaborates with scholars based in United States, Singapore and Italy. Carolyn A. Buser's co-authors include Stuart McLaughlin, Gary W. Brudvig, Marilyn D. Resh, Bruce A. Diner, Wenjun Zhou, George D. Hartman, Hans E. Huber, Lynmarie K. Thompson, Huifeng Liu and Raymond E. Meyn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Carolyn A. Buser

47 papers receiving 2.5k citations

Peers

Carolyn A. Buser
J. Breed United Kingdom
Daniella Zheleva United Kingdom
Salem Faham United States
Rüdiger Woscholski United Kingdom
Carolyn A. Buser
Citations per year, relative to Carolyn A. Buser Carolyn A. Buser (= 1×) peers Michel Vincent

Countries citing papers authored by Carolyn A. Buser

Since Specialization
Citations

This map shows the geographic impact of Carolyn A. Buser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carolyn A. Buser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carolyn A. Buser more than expected).

Fields of papers citing papers by Carolyn A. Buser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carolyn A. Buser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carolyn A. Buser. The network helps show where Carolyn A. Buser may publish in the future.

Co-authorship network of co-authors of Carolyn A. Buser

This figure shows the co-authorship network connecting the top 25 collaborators of Carolyn A. Buser. A scholar is included among the top collaborators of Carolyn A. Buser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carolyn A. Buser. Carolyn A. Buser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Concha, N.O., Angela Smallwood, William G. Bonnette, et al.. (2015). Long-Range Inhibitor-Induced Conformational Regulation of Human IRE1α Endoribonuclease Activity. Molecular Pharmacology. 88(6). 1011–1023. 42 indexed citations
2.
Dudkin, Vadim, Cheng Wang, Kenneth L. Arrington, et al.. (2012). Pyridyl aminothiazoles as potent Chk1 inhibitors: Optimization of cellular activity. Bioorganic & Medicinal Chemistry Letters. 22(7). 2613–2619. 6 indexed citations
3.
Bridges, Kathleen A., Hiroshi Hirai, Carolyn A. Buser, et al.. (2011). MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells. Clinical Cancer Research. 17(17). 5638–5648. 185 indexed citations
4.
Ivanovska, Irena L., Chunsheng Zhang, Angela M. Liu, et al.. (2011). Gene Signatures Derived from a c-MET-Driven Liver Cancer Mouse Model Predict Survival of Patients with Hepatocellular Carcinoma. PLoS ONE. 6(9). e24582–e24582. 26 indexed citations
5.
Luk, John M., Julja Burchard, Chunsheng Zhang, et al.. (2011). DLK1-DIO3 Genomic Imprinted MicroRNA Cluster at 14q32.2 Defines a Stemlike Subtype of Hepatocellular Carcinoma Associated with Poor Survival. Journal of Biological Chemistry. 286(35). 30706–30713. 126 indexed citations
6.
Dharmapuri, Sridhar, Daniela Peruzzi, Emanuele Marra, et al.. (2011). Intratumor RNA interference of cell cycle genes slows down tumor progression. Gene Therapy. 18(7). 727–733. 10 indexed citations
7.
Efferson, Clay L., Christopher T. Winkelmann, Christopher Ware, et al.. (2010). Downregulation of Notch Pathway by a γ-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model. Cancer Research. 70(6). 2476–2484. 76 indexed citations
8.
Marshall, C. Gary, Maricel Torrent, Olusegun Williams, Kelly Hamilton, & Carolyn A. Buser. (2009). Characterization of inhibitor binding to human kinesin spindle protein by site-directed mutagenesis. Archives of Biochemistry and Biophysics. 484(1). 1–7. 12 indexed citations
9.
Rickert, Keith, Michael D. Schaber, Maricel Torrent, et al.. (2007). Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Archives of Biochemistry and Biophysics. 469(2). 220–231. 40 indexed citations
10.
Roecker, Anthony J., Paul J. Coleman, Swati P. Mercer, et al.. (2007). Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters. 17(20). 5677–5682. 35 indexed citations
11.
12.
Fraley, Mark E., George D. Hartman, Carolyn A. Buser, et al.. (2005). Discovery of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Cancer Research. 65. 1463–1463. 1 indexed citations
13.
Dinsmore, Christopher J., C. Blair Zartman, Jeffrey M. Bergman, et al.. (2004). Macrocyclic piperazinones as potent dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I. Bioorganic & Medicinal Chemistry Letters. 14(3). 639–643. 8 indexed citations
14.
Buser, Carolyn A. & Stuart McLaughlin. (2003). Ultracentrifugation Technique for Measuring the Binding of Peptides and Proteins to Sucrose-Loaded Phospholipid Vesicles. Humana Press eBooks. 84. 267–282. 51 indexed citations
15.
Tucker, Thomas J., Marc Abrams, Carolyn A. Buser, et al.. (2002). The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases. Bioorganic & Medicinal Chemistry Letters. 12(15). 2027–2030. 13 indexed citations
16.
Huber, Hans E., R. Robinson, Deborah D. Nahas, et al.. (2001). Anions Modulate the Potency of Geranylgeranyl-Protein Transferase I Inhibitors. Journal of Biological Chemistry. 276(27). 24457–24465. 16 indexed citations
17.
Bergman, Jeffrey M., Marc Abrams, Joseph P. Davide, et al.. (2001). Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I. Bioorganic & Medicinal Chemistry Letters. 11(11). 1411–1415. 25 indexed citations
18.
Buser, Carolyn A., Christopher J. Dinsmore, Christine Fernandes, et al.. (2001). High-Performance Liquid Chromatography/Mass Spectrometry Characterization of Ki4B-Ras in PSN-1 Cells Treated with the Prenyltransferase Inhibitor L-778,123. Analytical Biochemistry. 290(1). 126–137. 24 indexed citations
19.
Beckmann, Peter A., Carolyn A. Buser, Clelia W. Mallory, Frank B. Mallory, & Jennifer J. Mosher. (1998). Methyl reorientation in solid 3-ethylchrysene and 3-isopropylchrysene. Solid State Nuclear Magnetic Resonance. 12(4). 251–256. 16 indexed citations
20.
Buser, Carolyn A., Lynmarie K. Thompson, Bruce A. Diner, & Gary W. Brudvig. (1990). Electron-transfer reactions in manganese-depleted photosystem II. Biochemistry. 29(38). 8977–8985. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026